Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
DNP – Die Neurologie & Psychiatrie
Erschienen in: DNP - Der Neurologe & Psychiater 2/2013

12.02.2013 | Zertifizierte Fortbildung

Kinderwunsch trotz Multipler Sklerose?

Immunmodulatorische Therapie

verfasst von: PD Dr. med. Kerstin Hellwig, Milena Rockhoff, Prof. Dr. med. Ralf Gold, Dr. med. Katrin Straßburger-Krogias

Erschienen in: DNP – Die Neurologie & Psychiatrie | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Multiple Sklerose ist die häufigste entzündliche ZNS-Erkrankung des jungen Erwachsenenalters. Während man früher Frauen mit Multipler Sklerose von eigenen Kindern abgeraten hat, ist die Erkrankung heute kein genereller Hinderungsgrund mehr für eine Schwangerschaft. Neue Herausforderungen liegen in der richtigen Beratung hinsichtlich der immunmodulatorischen Therapien im Zusammenhang mit der Familienplanung und ungeplanter Schwangerschaft.

Literatur
  1. Orton SM, Herrera BM, Yee IM, Valdar W, Ramagopalan SV, Sadovnick AD, et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol. [Comparative Study Research Support, Non-U.S. Gov’t]. 2006 Nov;5(11):932–936.PubMedView Article
  2. Cavalla P, Rovei V, Masera S, Vercellino M, Massobrio M, Mutani R, et al. Fertility in patients with multiple sclerosis: current knowledge and future perspectives. Neurol Sci. [Review]. 2006 Sep;27(4):231–239.PubMedView Article
  3. Jalkanen A, Alanen A, Airas L. Pregnancy outcome in women with multiple sclerosis: results from a prospective nationwide study in Finland. Mult Scler. [Multicenter Study Research Support, Non-U.S. Gov’t]. 2010 Aug;16(8):950–955.PubMedView Article
  4. Fachinformation. Betaferon® 250 Mikrogramm/ml. http://​wwwdeutschesapot​hekenportalde/​fileadmin/​bestellungen/​fi_​betaferonpdf. 2012.
  5. Cocco E, Sardu C, Gallo P, Capra R, Amato MP, Trojano M, et al. Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. Mult Scler. 2008 Nov;14(9):1225–1233.PubMedView Article
  6. Correale J, Farez MF, Ysrraelit MC. Increase in multiple sclerosis activity after assisted reproduction technology. Ann Neurol. 2012 Oct 3.
  7. Laplaud DA, Leray E, Barriere P, Wiertlewski S, Moreau T. Increase in multiple sclerosis relapse rate following in vitro fertilization. Neurology. [Case Reports]. 2006 Apr 25;66(8):1280–1281.PubMedView Article
  8. Michel L, Foucher Y, Vukusic S, Confavreux C, de Seze J, Brassat D, et al. Increased risk of multiple sclerosis relapse after in vitro fertilisation. J Neurol Neurosurg Psychiatry. [Research Support, Non-U.S. Gov’t]. 2012 Aug;83(8):796–802.PubMedView Article
  9. Hellwig K, Beste C, Brune N, Haghikia A, Muller T, Schimrigk S, et al. Increased MS relapse rate during assisted reproduction technique. J Neurol. [Letter Research Support, Non-U.S. Gov’t]. 2008 Apr;255(4):592–593.PubMedView Article
  10. Hrometz SL, Gates VA. Review of available infertility treatments. Drugs Today (Barc). [Review]. 2009 Apr;45(4):275–291.View Article
  11. Gold SM, Mohr DC, Huitinga I, Flachenecker P, Sternberg EM, Heesen C. The role of stress-response systems for the pathogenesis and progression of MS. Trends Immunol. [Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov’t Review]. 2005 Dec;26(12):644–652.
  12. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med. [Multicenter Study Research Support, Non-U.S. Gov’t]. 1998 Jul 30;339(5):285–291.PubMedView Article
  13. Hellwig K, Brune N, Haghikia A, Muller T, Schimrigk S, Schwodiauer V, et al. Reproductive counselling, treatment and course of pregnancy in 73 German MS patients. Acta Neurol Scand. [Research Support, Non-U.S. Gov’t]. 2008 Jul;118(1):24–28.PubMedView Article
  14. Park-Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett L, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. [Meta-Analysis]. 2000 Dec;62(6):385–392.PubMedView Article
  15. Koch M, Uyttenboogaart M, Heersema D, Steen C, De Keyser J. Parity and secondary progression in multiple sclerosis. J Neurol Neurosurg Psychiatry. [Research Support, Non-U.S. Gov’t]. 2009 Jun;80(6):676–678.PubMedView Article
  16. D’Hooghe M B, Nagels G, Uitdehaag BM. Long-term effects of childbirth in MS. J Neurol Neurosurg Psychiatry. 2010 Jan;81(1):38–41.PubMedView Article
  17. Ramagopalan S, Yee I, Byrnes J, Guimond C, Ebers G, Sadovnick D. Term pregnancies and the clinical characteristics of multiple sclerosis: a population based study. J Neurol Neurosurg Psychiatry. [Research Support, Non-U.S. Gov’t]. 2012 Aug;83(8):793–795.PubMedView Article
  18. Airas L, Saraste M, Rinta S, Elovaara I, Huang YH, Wiendl H. Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells. Clin Exp Immunol. [Research Support, Non-U.S. Gov’t]. 2008 Feb;151(2):235–243.PubMedView Article
  19. Voskuhl RR, Gold SM. Sex-related factors in multiple sclerosis susceptibility and progression. Nat Rev Neurol. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Review]. 2012 May;8(5):255–263.PubMedView Article
  20. van der Kop ML, Pearce MS, Dahlgren L, Synnes A, Sadovnick D, Sayao AL, et al. Neonatal and delivery outcomes in women with multiple sclerosis. Ann Neurol. 2011 Jun 27.
  21. Dahl J, Myhr KM, Daltveit AK, Hoff JM, Gilhus NE. Pregnancy, delivery, and birth outcome in women with multiple sclerosis. Neurology. 2005 Dec 27;65(12):1961–1963.PubMedView Article
  22. Dahl J, Myhr KM, Daltveit AK, Gilhus NE. Pregnancy, delivery and birth outcome in different stages of maternal multiple sclerosis. J Neurol. [Research Support, Non-U.S. Gov’t]. 2008 May;255(5):623–627.PubMedView Article
  23. Kelly VM, Nelson LM, Chakravarty EF. Obstetric outcomes in women with multiple sclerosis and epilepsy. Neurology. 2009 Dec 1;73(22):1831–1836.PubMedView Article
  24. Vukusic S, Hutchinson M, Hours M, Moreau T, Cortinovis-Tourniaire P, Adeleine P, et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain. 2004 Jun;127(Pt 6):1353–1360.PubMedView Article
  25. Borisow N, Doring A, Pfueller CF, Paul F, Dorr J, Hellwig K. Expert recommendations to personalization of medical approaches in treatment of multiple sclerosis: an overview of family planning and pregnancy. Epma J. 2012;3(1):9.PubMedView Article
  26. Houtchens MK, Kolb CM. Multiple sclerosis and pregnancy: therapeutic considerations. J Neurol. 2012 Aug 25.
  27. Geissbühler Y BH, Hernández-Diaz S, et al. Pregnancy outcomes from fingolimod clinical trials and post-marketing experience and the need for a multinational Gilenya™ (fingolimod) Pregnancy Exposure Registry in Multiple Sclerosis. ECTRIMS 2012; 12 Oct, 2012; Lyon, France Abstract 751. 2012.
  28. Stuve O BM, Benzerdjeb H, Kieseier B. Pregnancy Outcomes from the Teriflunomide Clinical Development Program: Retrospective Analysis of a Global Pharmacovigilance Database. Neurology. 2012;78(April 22):P06.190.
  29. Briggs GG, Freeman RK, Yaffe SJ. Classification of drugs for teratogenic risk: an anachronistic way of counseling: a reply to Merlob And Stahl. Birth Defects Res A Clin Mol Teratol. [Letter]. 2003 Mar;67(3):207–208.PubMedView Article
  30. Lu E, Wang BW, Guimond C, Synnes A, Sadovnick D, Tremlett H. Disease-modifying drugs for multiple sclerosis in pregnancy: A systematic review. Neurology. 2012 Aug 29.
  31. Amato MP, Portaccio E, Ghezzi A, Hakiki B, Zipoli V, Martinelli V, et al. Pregnancy and fetal outcomes after interferon-beta exposure in multiple sclerosis. Neurology. [Comparative Study Multicenter Study]. 2010 Nov 16;75(20):1794–1802.PubMedView Article
  32. Weber-Schoendorfer C, Schaefer C. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Mult Scler. [Research Support, Non-U.S. Gov’t]. 2009 Sep;15(9):1037–1042.PubMedView Article
  33. Sandberg-Wollheim M, Frank D, Goodwin TM, Giesser B, Lopez-Bresnahan M, Stam-Moraga M, et al. Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. Neurology. [Review]. 2005 Sep 27;65(6):802–806.PubMedView Article
  34. Sandberg-Wollheim M, Alteri E, Moraga MS, Kornmann G. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. Mult Scler. [Research Support, Non-U.S. Gov’t]. 2011 Apr;17(4):423–430.PubMedView Article
  35. Boskovic R, Wide R, Wolpin J, Bauer DJ, Koren G. The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort. Neurology. 2005 Sep 27;65(6):807–811.PubMedView Article
  36. Coyle PK JK, Pardo L, Stark Pregnancy outcomes in patients with multiple sclerosis treated with glatiramer acetate (Copaxone). Neurology. 2003;60: A60.
  37. Giannini M, Portaccio E, Ghezzi A, Hakiki B, Pasto L, Razzolini L, et al. Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurol. 2012;12:124.PubMedView Article
  38. Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler. [Research Support, Non-U.S. Gov’t]. 2011 Aug;17(8):958–963.PubMedView Article
  39. Cristiano L BC, Bloomgren G. Preliminary evaluation of pregnancy outcomes from the Tysabri® (natalizumab) Pregnancy Exposure Registry. ECTRIMS 2011; P1005. 2011.
  40. Hellwig K, Schimrigk S, Chan A, Epplen J, Gold R. A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis. J Neurol Sci. 2011 Aug 15;307(1-2):164–165.PubMedView Article
  41. De Santis M, Straface G, Cavaliere AF, Rosati P, Batocchi AP, Caruso A. The first case of mitoxantrone exposure in early pregnancy. Neurotoxicology. [Case Reports]. 2007 May;28(3):696–697.PubMedView Article
  42. Hellwig K KM, Gold R, Langer-Gould A. Exclusive breastfeeding reduces the risk of postpartum relapses-a prospective study from the German MS and pregnancy registry: Experience from a nationwide database. Neurology. 2011;76(4):A272.
  43. Langer-Gould A, Huang SM, Gupta R, Leimpeter AD, Greenwood E, Albers KB, et al. Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. Arch Neurol. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. 2009 Aug;66(8):958–963.PubMedView Article
  44. Portaccio E, Ghezzi A, Hakiki B, Martinelli V, Moiola L, Patti F, et al. Breastfeeding is not related to postpartum relapses in multiple sclerosis. Neurology. 2011 Jul 6.
  45. Airas L, Jalkanen A, Alanen A, Pirttila T, Marttila RJ. Breast-feeding, postpartum and prepregnancy disease activity in multiple sclerosis. Neurology. [Research Support, Non-U.S. Gov’t]. 2010 Aug 3;75(5):474–476.PubMedView Article
  46. Pakpoor J, Disanto G, Lacey MV, Hellwig K, Giovannoni G, Ramagopalan SV. Breastfeeding and multiple sclerosis relapses: a meta-analysis. J Neurol. 2012 May 23.
  47. Greenberger PA, Odeh YK, Frederiksen MC, Atkinson AJ, Jr. Pharmacokinetics of prednisolone transfer to breast milk. Clin Pharmacol Ther. [Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.]. 1993 Mar;53(3):324–328.PubMedView Article
  48. Kumar AR, Hale TW, Mock RE. Transfer of interferon alfa into human breast milk. J Hum Lact. [Case Reports]. 2000 Aug;16(3):226–228.PubMedView Article
  49. de Seze J, Chapelotte M, Delalande S, Ferriby D, Stojkovic T, Vermersch P. Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis. Mult Scler. [Clinical Trial Controlled Clinical Trial]. 2004 Oct;10(5):596–597.PubMedView Article
  50. Achiron A, Rotstein Z, Noy S, Mashiach S, Dulitzky M, Achiron R. Intravenous immunoglobulin treatment in the prevention of childbirth-associated acute exacerbations in multiple sclerosis: a pilot study. J Neurol. [Clinical Trial]. 1996 Jan;243(1):25–28.PubMedView Article
  51. Achiron A, Kishner I, Dolev M, Stern Y, Dulitzky M, Schiff E, et al. Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis. J Neurol. [Comparative Study]. 2004 Sep;251(9):1133–1137.PubMedView Article
  52. Haas J, Hommes OR. A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis. Mult Scler. [Comparative Study Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. 2007 Aug;13(7):900–908.PubMedView Article
  53. Hellwig K, Haghikia A, Gold R. Parenthood and immunomodulation in patients with multiple sclerosis. J Neurol. [Research Support, Non-U.S. Gov’t]. 2010 Apr;257(4):580–583.PubMedView Article
Metadaten
Titel
Kinderwunsch trotz Multipler Sklerose?
Immunmodulatorische Therapie
verfasst von
PD Dr. med. Kerstin Hellwig
Milena Rockhoff
Prof. Dr. med. Ralf Gold
Dr. med. Katrin Straßburger-Krogias
Publikationsdatum
12.02.2013
Verlag
Urban and Vogel
Erschienen in
DNP – Die Neurologie & Psychiatrie / Ausgabe 2/2013
Print ISSN: 2731-8168
Elektronische ISSN: 2731-8176
DOI
https://doi.org/10.1007/s15202-013-0067-0

Weitere Artikel der Ausgabe 2/2013

DNP - Der Neurologe & Psychiater 2/2013 Zur Ausgabe

Editorial

Hat die Psychopharmakotherapie noch eine Zukunft?

Medizin aktuell

Kopfeinsatz beim Sport rächt sich im Alter

Kurz gemeldet

App für Patienten mit Depression

Literatur kompakt

Neue Studien zur Schizophrenie

Kurz gemeldet

9. ADHS-Förderpreis verliehen

Pharmaforum

Oraler Immunmodulator reduziert Krankheitsprogression und Hirnatrophie bei MS

Neu in den Fachgebieten Neurologie und Psychiatrie

25.04.2024 | Hypotonie | Nachrichten

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 | AAN-Jahrestagung 2024 | Nachrichten

Frühe Alzheimertherapie lohnt sich

25.04.2024 | Parkinson-Krankheit | Nachrichten

Viel Bewegung in der Parkinsonforschung

23.04.2024 | Demenz | Nachrichten

Demenzkranke durch Antipsychotika vielfach gefährdet